OCT 14·SEC EDGARLow
Lin Yi-Chien purchased $6K of XAIR
Lin Yi-Chien purchased 2,607 shares of Beyond Air, Inc. (XAIR) at $2.21 on 2026-10-13.
StockNASDAQ · US · USDHealthcare · Medical Devices
$XAIR
Beyond Air, Inc.
AlphAI earnings readQuarter ended June 30, 2026 · AUG 18Beyond Air reported $1.8 million revenue for the quarter ended June 30, 2026, reaffirmed calendar-year 2026 revenue guidance of $8 million and calendar-year 2027 guidance of $16-$18 million, and cited pending FDA review of its second-generation LungFit PH PMA supplement.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $XAIRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $XAIR in the last 7 days.
Insider · 30dAll trades →
- Buys
- $62K 4 txs
- Sells
- — 0 txs
Lin Yi-Chien4× · $62K
10b5-1 share of filings0%
Top stories · $XAIRMore →
OCT 8·SEC EDGAR 8-K
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye
OCT 8·investing.com
Beyond Air reports preliminary Q3 revenue of $2.3 million
Beyond Air Inc. (XAIR) reported preliminary Q3 2026 revenue of $2.3M, up 30% QoQ and 27% YoY, its highest quarterly revenue. The growth was driven by its LungFit PH system. The company reaffirmed its 2026 revenue guidance of $8M and 2027 guidance of $16M-$18M, pending FDA approval for its second-generation system. Final results are expected in November 2026.
XAIR sentiment & insider activity
Recent XAIR coverage spans insider activity, earnings and financial news.
In the last 30 days, XAIR insiders filed 4 SEC Form 4 transactions — 4 purchases ($62K) and no sales. The most active reporter was Lin Yi-Chien with 4 filings.
What's driving XAIR
Small insider purchase adds modest buying pressure.
Preliminary revenue growth and reaffirmed guidance support the near-term revenue trajectory, but FDA review timing for second-generation LungFit PH remains a key overhang.
Preliminary revenue beat expectations for a microcap, likely supporting short-term price upside.
Potential buying pressure as insider accumulates shares.
Insider purchase suggests confidence, may create modest buying pressure.
AlphAI scores every news story that mentions XAIR with an AI model for sentiment and relevance, and aggregates insider trades from Beyond Air, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $XAIR
Score
Lin Yi-Chien purchased $6K of XAIR
Lin Yi-Chien purchased 2,607 shares of Beyond Air, Inc. (XAIR) at $2.21 on 2026-10-13.
1 min readBeyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye
3 min readBeyond Air reports preliminary Q3 revenue of $2.3 million
Beyond Air Inc. (XAIR) reported preliminary Q3 2026 revenue of $2.3M, up 30% QoQ and 27% YoY, its highest quarterly revenue. The growth was driven by its LungFit PH system. The company reaffirmed its 2026 revenue guidance of $8M and 2027 guidance of $16M-$18M, pending FDA approval for its second-generation system. Final results are expected in November 2026.
1 min readTop insider buys and sells disclosed on Friday
Beyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.
3 min readLin Yi-Chien purchased $57K of XAIR
Lin Yi-Chien purchased 20,393 shares of Beyond Air, Inc. (XAIR) at an average of $2.78 ($2.69–$2.80) across 3 trades over 2026-09-29 to 2026-10-01.
1 min readBeyond Air, Inc. (XAIR): Entry into a Material Definitive Agreement
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The description in Item 5.02 below, as it relates to the terms and conditions of the Employment Agreement with Mr. Goodman, a copy of which is filed herewith as Exhibit 10.1, is incorporated herein by reference. Item 5.02. Dep
1 min readXAIR Initiates Coverage On Beyond Air -- Rating Set to Buy
Beyond Air (XAIR) received a 'Buy' rating and $10 price target from Lake Street. Analysts see potential in its nitric oxide delivery systems, but the company faces financial challenges, with a GF Score of 23/100 and a market cap of $3.75M. Insiders recently bought shares, and the stock is deemed 99.1% undervalued by GF Value.
2 min readBeyond Air Receives FDA Breakthrough Device Designation For LungFit GO In NTM-PD
Beyond Air (XAIR) received FDA Breakthrough Device Designation for LungFit GO, a portable nitric oxide therapy for NTM-PD. A pilot study showed safety, compliance, and quality-of-life improvements. The designation may accelerate clinical studies. XAIR closed at $4.48, up 4.10% in pre-market trading.
2 min readBeyond Air Enters Definitive Agreement With UNIVO For NeuroNOS Stake; Stock Down
Beyond Air (XAIR) agreed to sell its 58% stake in NeuroNOS to UNIVO for equity and milestone payments. Beyond Air will receive 19.99% of UNIVO's shares and warrants, plus up to $32.5M in milestone payments. XAIR closed at $4.91, down 2.58%.
2 min readLucid, Beyond Air, Conagra Stocks Hit 52-Week Lows: What's Behind The Drag?
Lucid Group (LCID), Beyond Air (XAIR), and Conagra Brands (CAG) hit 52-week lows. LCID's outlook weakened due to lower revenue expectations and a stock offering, with analysts cutting price targets. XAIR received a Nasdaq compliance notice, while CAG faces earnings pressure from inflation and a recent CEO change.
2 min read